Fortress Biotech, Inc. - Dec 31, 2024 Form 4 Insider Report for Checkpoint Therapeutics, Inc. (CKPT)

Role
10%+ Owner
Signature
/s/ Samuel Berry, Attorney-in-Fact
Stock symbol
CKPT
Transactions as of
Dec 31, 2024
Transactions value $
$0
Form type
4
Date filed
1/3/2025, 04:15 PM
Previous filing
Oct 1, 2024
Next filing
Feb 27, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CKPT COMMON STOCK, PAR VALUE $0.0001 Award $0 +81.4K +2.18% $0.00 3.82M Dec 31, 2024 Direct F1
transaction CKPT COMMON STOCK, PAR VALUE $0.0001 Award $0 +2.39M +62.53% $0.00 6.2M Jan 1, 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the exercise of warrants.
F2 The Reporting Person is entitled to an annual equity fee grant from the issuer of a number of shares of the Issuer's Common Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. These shares were granted by the Issuer to the Reporting Person for the 2024 annual equity fee grant.